A phase Ib single-arm study of bintrafusp alfa for the treatment of pretreated, locally advanced/unresectable or metastatic urothelial cancer.

被引：2
|
作者：
Grivas, Petros [1 ]
Morales-Barrera, Rafael [2 ]
Sridhar, Srikala S. [3 ]
Loriot, Yohann [4 ]
Van der Heijden, Michiel Simon [5 ]
Galsky, Matt D. [6 ]
Baxter, Dawn [7 ]
Khaled, Ahmed Hussein [7 ]
Hug, Bruce A. [7 ]
机构：
[1] Univ Washington, Fred Hutchinson Canc Res Ctr, Dept Med, Div Oncol,Seattle Canc Care Alliance, Seattle, WA 98195 USA
[2] Univ Autonoma Barcelona, Vall dHebron Univ Hosp, Vall dHebron Inst Oncol, Barcelona, Spain
[3] Princess Margaret Canc Ctr, Canc Clin Res Unit, Toronto, ON, Canada
[4] Univ Paris Saclay, Inst Gustave Roussy, Dept Canc Med, Villejuif, France
[5] Netherlands Canc Inst, Amsterdam, Netherlands
[6] Icahn Sch Med Mt Sinai, Tisch Canc Inst, Dept Med, Div Hematol Oncol, New York, NY 10029 USA
[7] GlaxoSmithKline, Collegeville, PA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.TPS501
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS501
引用
收藏
页数：2
相关论文
共 50 条
  • [1] A phase Ib single-arm trial of bintrafusp alfa (BA) for pretreated, locally advanced/unresectable or metastatic (advanced) urothelial cancer (aUC)
    Grivas, P.
    Sridhar, S.
    Perez Valderrama, B.
    Castellano Gauna, D. E.
    Loriot, Y.
    Doger de Speville, B.
    Pouessel, D.
    van der Heijden, M. S.
    Galsky, M. D.
    Gulati, S.
    Ravaud, A.
    Fontana, E.
    Spira, A. I.
    Gartrell, B. A.
    Mortazavi, A.
    Isambert, N.
    Baxter, D.
    Powles, T. B.
    Khaled, A. H.
    Morales Barrera, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1209 - S1210
  • [2] Bintrafusp alfa plus paclitaxel for advanced gastric cancer as a second-line treatment: An open label, single-arm, phase Ib/II study.
    Lee, Choong-kun
    Jung, Minkyu
    Park, Sejung
    Kwon, Woo Sun
    Kim, Kyoo Hyun
    Hong, Moonki
    Kim, Hyunwook
    Kim, Hyo Song
    Chung, Hyun Cheol Cheol
    Rha, Sun Young
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 374 - 374
  • [3] A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
    Sonpavde, Guru
    Maughan, Benjamin Louis
    Wei, Xiao X.
    McGregor, Bradley Alexander
    Kilbridge, Kerry L.
    Lee, Richard J.
    Yu, Evan
    Schweizer, Michael Thomas
    Montgomery, Robert B.
    Cheng, Heather H.
    Hsieh, Andrew Caleb
    Birhiray, Ruemu E.
    Gabrail, Nashat Y.
    Nemunaitis, John J.
    Rezazadeh, Arash
    Van Veldhuizen, Peter J.
    Vogelzang, Nicholas J.
    Heery, Christopher Ryan
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [4] First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
    Balar, Arjun V.
    Castellano, Daniel
    O'Donnell, Peter H.
    Grivas, Petros
    Vuky, Jacqueline
    Powles, Thomas
    Plimack, Elizabeth R.
    Hahn, Noah M.
    de Wit, Ronald
    Pang, Lei
    Savage, Mary J.
    Perini, Rodolfo F.
    Keefe, Stephen M.
    Bajorin, Dean
    Bellmunt, Joaquim
    LANCET ONCOLOGY, 2017, 18 (11): : 1483 - 1492
  • [5] Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
    Li, H.
    Chen, M.
    Xue, C.
    Li, L.
    Hu, A.
    Yang, W.
    Zheng, Z.
    Ni, M.
    Zhang, L.
    Zeng, Y.
    Peng, J.
    Yao, K.
    Zhou, F.
    Liu, Z.
    An, X.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1335 - S1335
  • [6] AN0025 in combination with definitive chemoradiotherapy (dCRT) in unresectable locally advanced or locally recurrent esophageal cancer (EC): A single-arm, open-label, multicenter, phase Ib study
    Bi, Nan
    Liu, Fang
    Hu, Ying
    Wang, Wei
    Liu, Wenyang
    Liu, Rongrui
    Liu, Yanli
    Zhang, Pei
    Zhao, Chuan Hua
    Chen, Jing
    Luo, Lingrong
    Huang, Zaijie
    Gu, Mengjie
    Tang, Kaiyang
    Lu, Xuyang
    Song, Xuyang
    Zhao, Tianyi
    Wang, Yuan
    Liang, Hongming
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [7] A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer.
    Hu, Nanlin
    Yuan, Peng
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [8] Cohort study of metastatic and unresectable, locally advanced urothelial carcinoma
    Rexer, Heidrun
    Schnabel, Marco J.
    Retz, Margitta
    AKTUELLE UROLOGIE, 2024, 55 (03)
  • [9] Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
    Li, J-R.
    Feng, Y-H.
    Chen, C-H.
    Ku, W-H.
    Huang, H-L.
    Huang, W. J-S.
    ANNALS OF ONCOLOGY, 2022, 33 : S1489 - S1489
  • [10] Treatment outcomes and FGFR alterations in unresectable locally advanced or metastatic urothelial cancer in Taiwan
    Li, J-R.
    Feng, Y-H.
    Chen, C-H.
    Ku, W-H.
    Huang, H-L.
    Huang, W. J-S.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1349 - S1350
12345